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Protein tyrosine phosphatase 1B modulates
GSK3b/Nrf2 and IGFIR signaling pathways in
acetaminophen-induced hepatotoxicity
MA Mobasher1,2, A´ Gonza´lez-Rodriguez1,2, B Santamarı´a1,2, S Ramos3, MA´ Martı´n2,3, L Goya3, P Rada1,4, L Letzig5,
LP James5, A Cuadrado1,4, J Martı´n-Pe´rez1, KJ Simpson6, J Muntane´7,8 and AM Valverde*,1,2
Acute hepatic failure secondary to acetaminophen (APAP) poisoning is associated with high mortality. Protein tyrosine
phosphatase 1B (PTP1B) is a negative regulator of tyrosine kinase growth factor signaling. In the liver, this pathway confers
protection against injury. However, the involvement of PTP1B in the intracellular networks activated by APAP is unknown. We
have assessed PTP1B expression in APAP-induced liver failure in humans and its role in the molecular mechanisms that
regulate the balance between cell death and survival in human and mouse hepatocytes, as well as in a mouse model of APAP-
induced hepatotoxicity. PTP1B expression was increased in human liver tissue removed during liver transplant from patients for
APAP overdose. PTP1B was upregulated by APAP in primary human and mouse hepatocytes together with the activation of c-jun
(NH2) terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK), resulting in cell death. Conversely, Akt
phosphorylation and the antiapoptotic Bcl2 family members BclxL and Mcl1 were decreased. PTP1B deficiency in mouse
protects hepatocytes against APAP-induced cell death, preventing glutathione depletion, reactive oxygen species (ROS)
generation and activation of JNK and p38 MAPK. APAP-treated PTP1B / hepatocytes showed enhanced antioxidant defense
through the glycogen synthase kinase 3 (GSK3)b/Src kinase family (SKF) axis, delaying tyrosine phosphorylation of the
transcription factor nuclear factor-erythroid 2-related factor (Nrf2) and its nuclear exclusion, ubiquitination and degradation.
Insulin-like growth factor-I receptor-mediated signaling decreased in APAP-treated wild-type hepatocytes, but was maintained in
PTP1B / cells or in wild-type hepatocytes with reduced PTP1B levels by RNA interference. Likewise, both signaling cascades
were modulated in mice, resulting in less severe APAP hepatotoxicity in PTP1B / mice. Our results demonstrated that PTP1B
is a central player of the mechanisms triggered by APAP in hepatotoxicity, suggesting a novel therapeutic target against APAP-
induced liver failure.
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Acetaminophen (APAP) or paracetamol is a widely used
analgesic and antipyretic, which is drug safe at therapeutic
doses,1 but accidental or intentional overdose induces severe
hepatotoxicity in experimental animals and humans. APAP
overdose is the most frequent cause of drug-induced liver
failure in the United States2,3 and most of Europe.4,5 In these
countries, APAP is a leading cause of urgent liver transplanta-
tion, which accounts for considerable levels of morbidity and
mortality.2 Therefore, APAP-induced acute toxicity has
become an essential model for studying drug-induced
liver and kidney failure. In the liver, APAP overdose
produces centrilobular hepatic necrosis that can be fatal as
it progresses to fulminant liver failure.6 However, despite
substantial progress in understanding APAP-induced
hepatotoxicity,7–9 additional injurious mechanisms responsi-
ble for the cellular damage induced by APAP remain unknown.
At normal dosage, the major elimination pathways of APAP
involve glucuronide and sulfate conjugation. The initial step in
toxicity is bioactivation of APAP by cytochrome P450 2e1
(Cyp2e1) to an electrophilic metabolite, N-acetyl-p-amino-
benzoquinone imine (NAPQI).10 At therapeutic doses, NAPQI
is detoxified by glutathione (GSH) and eliminated in urine
or bile as APAP-cysteine, APAP-N-acetylcysteine and
APAP-APAP-GSH.11 After an overdose, glucuronidation and
sulfation routes become saturated and more extensive
bioactivation of APAP occurs, leading to rapid depletion of
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the hepatic GSH pool. Subsequently, NAPQI binds to cysteine
groups on cellular proteins forming APAP–protein adducts.
NAPQI also binds to mitochondrial proteins, which, in turn,
causes oxidative stress that may trigger signaling pathways
through mitochondrial toxicity, leading to lethal cell injury.
Moreover, generation of reactive oxygen (ROS) and nitrogen
species, lipid peroxidation, mitochondrial dysfunction, disrup-
tion of calcium homeostasis and induction of apoptosis and
necrosis are also involved in APAP-induced hepatotoxicity.12–
14 Therefore, tight control of ROS levels by antioxidant
molecules and detoxifying enzymes is important to restore
the balance between oxidants and antioxidants in cells
challenged with oxidative insults. In this regard, nuclear factor
erythroid-2-related factor 2 (Nrf2) activates detoxifying
enzymes by binding to antioxidant response elements
(AREs). Nrf2-deficient mice are highly susceptible to APAP-
induced liver injury.15 Thus, Nrf2 may serve as an endogen-
ous regulator by which cells combat oxidative stress.
Protein tyrosine phosphorylation is crucial in the mechan-
isms by which growth factors and hormones regulate cellular
metabolism, differentiation, growth and survival. Given the
importance in maintaining survival and death fates of cells, the
balance between tyrosine kinases and phosphatases is
carefully regulated. Protein tyrosine phosphatases (PTPs)
catalyze dephosphorylation of tyrosine-phosphorylated
proteins.16 Among them, protein tyrosine phosphatase 1B
(PTP1B) is a widely expressed non-receptor PTP, which is
associated with the endoplasmic reticulum by interaction
through the C-terminal domain.17 PTP1B has been proposed
as a therapeutic target against type 2 diabetes and obesity
via its capacity to dephosphorylate insulin and leptin
receptors.18,19 PTP1B also dephosphorylates and inactivates
receptors of the tyrosine kinase superfamily, such as
EGF receptor, PDGF receptor,20 hepatocyte growth factor
receptor/met 21 and insulin-like growth factor-I receptor
(IGFIR),22 which are involved in hepatocyte survival.23,24 On
this basis, the aim of this study was to investigate the role of
PTP1B in APAP-induced hepatotoxicity.
Results
PTP1B expression increased during APAP-induced
liver injury in human liver and APAP-treated human
hepatocytes. We investigated if PTP1B was modulated
during APAP-induced human liver injury. Figure 1a shows
elevated PTP1B in surviving hepatocytes, mainly in the areas
surrounding the central veins (middle panel), during APAP
intoxication as compared with a normal liver (left panel). In a
more severe intoxication (right panel), where it is difficult to
detect surviving hepatocytes, strong staining was observed in
precipitated proteins released from dead cells and not yet
cleared. PTP1B protein content was also upregulated in
human primary hepatocytes and in the human Chang liver cell
line (CHL) treated with APAP in a dose- and time-dependent
manner (Figures 1b and c and Supplementary Figure 1).
Elevation of PTP1B was detected at 8 h after APAP addition,
whereas cells with death morphology were visualized at 16 h.
Moreover, in APAP-treated human hepatocytes activation of
c-jun (NH2) terminal kinase (JNK) and p38 mitogen-activated
protein kinase (p38 MAPK) and inhibition of Akt phosphoryla-
tion correlated with decreased levels of the antiapoptotic Bcl2
family members BclxL and Mcl1 and with detection of the
active caspase-3 fragment (Figure 1d).
PTP1B-deficient mouse hepatocytes are protected
against APAP-induced necrotic and apoptotic cell death.
As observed in human hepatocytes (Figure 1c), PTP1B was
upregulated in primary hepatocytes from wild-type (PTP1Bþ /þ )
mice treated with APAP (10 mM) at 8 h, whereas maximal cell
death was observed at 16 h (Figure 2a). Next, we explored
APAP-induced hepatotoxicity in mouse primary hepatocytes
from wild-type and PTP1B / mice. Cells were treated with
5 and 10 mM APAP for 16 h and cell death was analyzed.
Phase-contrast microscopy revealed many APAP-treated
wild-type primary hepatocytes with cell death morphology.
Conversely, most of PTP1B / primary hepatocytes
remained attached to the plate and only few cells displayed
a death phenotype (Figure 2b). Quantification analysis of
crystal violet staining and released lactate dehydrogenase
(LDH) activity showed that primary PTP1B / hepatocytes
were more protected against APAP-induced necrotic cell
death. Moreover, APAP treatment also increased the
incidence of condensed and/or fragmented nuclei and the
percentage of hypodiploid (sub-G0/G1) population in wild-
type primary hepatocytes indicating apoptotic cell death
(Figure 2c). These effects were reduced in PTP1B / cells.
Apoptosis in APAP-treated wild-type primary hepatocytes
correlated with the release of cytochrome C from the
mitochondrial compartment and with the subsequent activa-
tion of caspase-3 (Figure 2d). These effects were signifi-
cantly ameliorated in PTP1B / primary hepatocytes.
Similar results were obtained using wild-type and PTP1B /
 immortalized hepatocytes that express comparable levels
of pro- and antiapoptotic proteins than primary hepatocytes
and are highly sensitive to APAP-induced cell death25
(Supplementary Figure 2).
Effect of PTP1B deficiency on the activation of stress-
and survival-mediated signaling pathways in mouse
hepatocytes. Next, we analyzed stress- and survival-
mediated signaling in primary hepatocytes from wild-type
and PTP1B / mice in response to APAP. JNK and p38
MAPK phosphorylation was detected at 8 h in primary
hepatocytes treated with 10 mM APAP, this effect being
ameliorated in PTP1B / cells (Figure 3a). Survival signal-
ing monitored by IGFIR phosphorylation, levels of insulin
receptor substrates 1 (IRS1) and 2 (IRS2) and Akt
phosphorylation, was reduced in APAP-treated wild-type
primary hepatocytes, but preserved in PTP1B / cells.
Consistently, the antiapoptotic markers BclxL and Mcl1 were
decreased in wild-type primary hepatocytes treated with
APAP but, again, this effect was reduced in PTP1B /
hepatocytes. Similar responses were found in immortalized
hepatocytes that activate stress kinases at lower APAP
doses (Figure 3b).
To exclude the possibility that the protection elicited by
PTP1B deficiency against APAP-induced cell death could be
secondary to compensatory adaptations in PTP1B /
hepatocytes, we established siRNA assays. Reduction of
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PTP1B in wild-type immortalized hepatocytes decreased
APAP-induced JNK phosphorylation and levels of the active
caspase-3 fragment, and also maintained IGFIR tyrosine
phosphorylation, IRS1 and IRS2 expression, Akt phosphory-
lation and abolished downregulation of BclxL upon APAP
treatment (Figure 3c).
PTP1B deficiency protects mouse hepatocytes against
GSH depletion and elevation of ROS by prolonging Nrf2
nuclear accumulation. In the liver, Cyp2e1 converts APAP
to NAPQI that depletes GSH and, therefore, the degree of
GSH consumption is a biomarker for APAP bioactivation.26 As
the expression of Cyp2e1 did not change in primary and
immortalized hepatocytes from both genotypes of mice
(Supplementary Figure 3), we used immortalized cells for
further experiments. APAP induced depletion of GSH in
wild-type immortalized hepatocytes after 4 h, and this effect
was absent in PTP1B / cells (Figure 4a). Likewise, a
significant elevation of ROS was detected in APAP-treated
wild-type hepatocytes for 6 h, but not in PTP1B / cells. Next,
we measured the enzymatic activity of the detoxifying enzymes
glutathione peroxidase (GPx) and glutathione reductase (GR).
GPx activity increased in APAP-treated wild-type hepatocytes
compared with untreated controls, as expected for an
antioxidant defense system. Conversely, GR was not
increased by APAP, suggesting impairment in pathways
replenishing GSH stores. PTP1B /hepatocytes did not
activate the GPx/GR system in response to APAP, probably
due to an insufficient threshold to trigger the activation of
detoxifying enzymes under these experimental conditions.
To investigate at the molecular level the mechanisms for
protection of PTP1B deficiency against APAP-induced
Figure 1 PTP1B expression is increased during APAP-induced liver injury and in human primary hepatocytes treated with APAP. (a) Representative anti-PTP1B
immunostaining of liver biopsy sections from patients with histologically normal liver (NL) or with an APAP overdose (APAP) (n¼ 7). Bar¼ 50mm. (b) Human primary
hepatocytes were treated with various doses of APAP (5–20 mM) for 24 h. Total cell lysates were analyzed by western blot with the antibodies against PTP1B and b-actin as a
loading control. Autoradiograms corresponding were quantitated by scanning densitometry. Results are means±S.E.M. *Po0.05 and ***Po0.005 APAP-treated versus
non-treated cells. Representative phase-contrast microscopy images after APAP treatment. Bar¼ 100mm. (c) Human primary hepatocytes were treated with 20 mM APAP for
various time-periods (4, 8 and 24 h). Total cell lysates were analyzed by western blot with the antibodies against PTP1B and b-actin as a loading control. Autoradiograms
corresponding were quantitated by scanning densitometry. Results are means±S.E.M. *Po0.05 APAP-treated versus non-treated cells. Representative phase-contrast
microscopy images after APAP treatment. Bar¼ 100mm. (d) Human primary hepatocytes were treated with various doses of APAP for 24 h and total cell lysates were
analyzed by western blot with the antibodies against phospho (p)-JNK1/2, JNK1/2, phospho-p38, p38, active caspase-3, phospho-Akt, Akt, BclxL, Mcl1 and p85-PI3K as a
loading control. *Po0.05 and ***Po0.005 APAP-treated versus non-treated cells (n¼ 3 independent experiments)
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oxidative stress, we analyzed the dynamics of Nrf2 nuclear
accumulation. As no differences in Nrf2 serine phosphoryla-
tion that dissociates Nrf2 to its inhibitor Keap1 at early time-
periods upon APAP treatment were found (Supplementary
Figure 4A), we analyzed the nuclear accumulation of Nrf2 at
later time-periods. Western blot and immunofluorescence
revealed that Nrf2 was maximally accumulated in the nucleus
at 8 h after APAP treatment in wild-type and PTP1B /
hepatocytes, but was retained for up to 16 h exclusively in
PTP1B / cells (Figure 4b). Nuclear Nrf2 accumulation was
accompanied by decreases in cytosolic expression
(Supplementary Figure 4B).
Tyrosine phosphorylation of Nrf2 results in its nuclear
export, ubiquitination and degradation in the cytosol.27
Figure 4c shows that in APAP-treated wild-type hepatocytes,
maximal Nrf2 tyrosine phosphorylation was observed at
8 h and total Nrf2 protein content decreased at 16 h. In
PTP1B / cells, maximal Nrf2 tyrosine phosphorylation
Figure 2 PTP1B-deficient primary hepatocytes are protected against APAP-induced cell death. (a, left panel) Wild-type (PTP1Bþ /þ ) mouse primary hepatocytes were
treated with 10 mM APAP for various time-periods. The expression of PTP1B was analyzed by western blot. *Po0.05 APAP-treated versus non-treated cells (n¼ 3
independent experiments). (Right panel) Representative phase-contrast microscopy images and analysis of the percentage of sub-G0/G1 cell population by flow cytometry.
(b) PTP1Bþ /þ and PTP1B / primary hepatocytes were treated with APAP (5 and 10 mM) for 16 h. (Left panel) Representative phase-contrast microscopy images.
Bar¼ 100mm. (Right panel) Cellular viability and released LDH activity. (c) PTP1Bþ /þ and PTP1B / primary hepatocytes were treated with APAP (5 and 10 mM) for 16 h.
(Left panel) Representative nuclear morphology images after DAPI staining and analysis by fluorescence microscopy. (Right panel) Quantification of apoptotic nuclei.
Percentage of sub-G0/G1 cell population analyzed by flow cytometry. (d, left panel) PTP1B
þ /þ and PTP1B / primary hepatocytes were treated with APAP (5 and 10 mM)
for 16 h. Western blot with anticytochrome C and anti-cytochrome C oxidase antibodies in mitochondrial extracts. (Right panel) PTP1Bþ /þ and PTP1B / primary
hepatocytes were treated with APAP (10 mM) for various time-periods. Analysis of caspase-3 enzymatic activity. *Po0.05, **Po0.01 and ***Po0.005 PTP1B / versus
PTP1Bþ /þ (n¼ 4 independent experiments)
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occurred at 16 h, a time-point at which total Nrf2 levels were
maintained as in non-treated cells. These data correlated with
greater increase in the expression of the Nrf2 target heme
oxygenase-1 (HO-1) in PTP1B / hepatocytes. As occurred
in immortalized hepatocytes, Nrf2 levels were maintained and
the induction of HO-1 was higher in APAP-treated mouse
primary PTP1B / hepatocytes for 16 h as compared with
the wild-type cells.
Next, ubiquitination analysis of Nrf2 was performed in
immortalized hepatocytes treated with APAP for 8–24 h either
in the absence or presence of the proteasome inhibitor MG132
(Figure 4d). In APAP-treated wild-type cells, ubiquitinated Nrf2
was detected at earlier time-points (8 h) compared with
PTP1B / cells, which displayed this response at 16 h; this
effect was enhanced when APAP was added with MG132. In
related experiments, overexpression of PTP1B in HEK 293T
cells inhibited ARE-mediated luciferase expression after treat-
ment with APAP for 16 h (Figure 4e), reinforcing the involvement
of PTP1B in Nrf2-mediated antioxidant response to APAP.
PTP1B modulates GSK3b/SKF-mediated Nrf2 nuclear
accumulation in APAP-treated mouse hepatocytes. In
response to oxidative stress, GSK3b is activated by
phosphorylation at Tyr216 by an unknown tyrosine kinase.
Activated GSK3b phosphorylates and activates Src kinase
family (SKF) members in the cytosol, allowing their nuclear
translocation and subsequent tyrosine phosphorylation of
Nrf2 at Tyr568, ultimately resulting in Nrf2 nuclear exclusion
and degradation.27,28 We examined if this molecular
mechanism was triggered in APAP-treated hepatocytes.
Silencing GSK3b in immortalized wild-type hepatocytes
(Supplementary Figure 5) prolonged Nrf2 nuclear accumula-
tion up to 24 h upon APAP treatment as observed in
PTP1B / cells (Figures 4b and 5a). Moreover, nuclear
translocation of Fyn and Src was also impaired in
GSK3b-silenced cells, although no effects of nuclear
translocation of Yes were observed (results not shown). To
reinforce the role of SKF in nuclear accumulation of Nrf2 in
response to APAP, we treated wild-type hepatocytes with the
Figure 3 Effect of PTP1B deficiency in stress and survival signaling in hepatocytes. (a, left panel) PTP1Bþ /þ and PTP1B / mouse primary hepatocytes were treated
with APAP (10 mM) for various time periods. Total cell lysates were analyzed by western blot with the antibodies against phospho (p)-JNK1/2, JNK1/2, phospho-p38 MAPK
and p38 MAPK. Representative autoradiograms corresponding to three independent experiments are shown. (Right panel) PTP1Bþ /þ and PTP1B / mouse primary
hepatocytes were treated with APAP (5 and 10 mM) for 16 h. Total cell lysates were analyzed by western blot with the antibodies against phospho (p)-IGFIR, IGFIR, IRS1,
IRS2, phospho-Akt, Akt, BclxL, Mcl1 and b-actin as a loading control. Representative autoradiograms corresponding to three independent experiments are shown.
(b) PTP1Bþ /þ and PTP1B / immortalized hepatocytes were treated with various doses of APAP for 16 h. Total cell lysates were analyzed by western blot with the
indicated antibodies. Representative autoradiograms corresponding to three independent experiments are shown. (c) Immortalized PTP1Bþ /þ hepatocytes transfected with
10 nM of control or PTP1B small interfering RNA (siRNA) for 48 h were further treated with various doses of APAP for 16 h. Total cell lysates were analyzed by western blot with
the indicated antibodies. Representative autoradiograms corresponding to three independent experiments are shown
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Figure 4 PTP1B deficiency protects hepatocytes against GSH depletion and elevation of ROS; effect on nuclear Nrf2 accumulation. PTP1Bþ /þ and PTP1B /
immortalized hepatocytes were treated with various doses of APAP for different time-periods. (a) Analysis of GSH content (4 h), ROS levels (6 h) and GPx and GR activity
(16 h) in three independent experiments. *Po0.05, **Po0.01 and ***Po0.005 PTP1B / versus PTP1Bþ /þ (b, upper panel) Analysis of Nrf2 in nuclear cell lysates by
western blot in PTP1Bþ /þ and PTP1B / immortalized hepatocytes treated with 1 mM APAP for several time-periods. Representative autoradiograms of three to four
independent experiments are shown. (Lower panel) Representative images corresponding to the intracellular localization of Nrf2 by immunofluorescence microscopy in
PTP1Bþ /þ and PTP1B / immortalized hepatocytes treated with 1 mM APAP for several time-periods. Bar¼ 50mm. (c) (Upper panel) PTP1Bþ /þ and PTP1B /
immortalized hepatocytes were treated with 1 mM APAP for several time-periods. Nrf2 tyrosine phosphorylation was analyzed by immunoprecipitation with the anti-Nrf2
antibody, followed by western blot with the anti-Tyr(P) antibody. Total Nrf2 and HO-1 was analyzed by western blot. (Lower panel) PTP1Bþ /þ and PTP1B / mouse
primary hepatocytes were treated with 10 mM APAP for various time-periods. Total Nrf2 and HO-1 was analyzed by western blot. (d) PTP1Bþ /þ and PTP1B /
immortalized hepatocytes were treated with MG132 (10 nM) for 30 min, and then with 1 mM APAP for different time-periods. Whole-cell lysates were analyzed by
immunoprecipitation with anti-Nrf2 antibody, followed by western blot with anti-ubiquitin antibody. (e) Antioxidant response element (ARE)-mediated luciferase activity was
measured in HEK 293T cells transfected with the expression vectors for pcDNA3.1mNrf2-V5/HisB and 3ARE-Luc combined with myc-PTP1B only in the indicated cases
and treated with various doses of APAP for 16 h. tBHQ (15 mM) was used as a positive control (n¼ 3 independent experiments performed in triplicate). ***Po0.005 PTP1B-
transfected (Nrf2 AREþPTP1B) versus empty vector-transfected (Nrf2 ARE) cells
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SKF inhibitor PP2. As shown in Figure 5b, PP2 increased
nuclear Nrf2 levels at 2–8 h after APAP treatment. In
addition, in mouse embryonic fibroblasts (MEFs) deficient
in SKF (SYF / ) treated with APAP Nrf2 was accumulated
in the nucleus up to 24 h.
We next analyzed the effect of PTP1B deficiency on the
GSK3b/SKF signaling pathway. In wild-type cells, APAP-
induced GSK3b tyrosine phosphorylation was detected at 1 h
and peaked at 4 h. This response paralleled the re-entry of
Fyn and Src into the nucleus (Figure 5c). In PTP1B /
hepatocytes, maximal GSK3b phosphorylation occurred
later at 8–16 h after APAP treatment and also paralleled
the re-entry of Src and Fyn into the nucleus as observed in
wild-type cells.
PTP1B-deficient mice are protected against APAP-
induced oxidative stress through the enhancement of
Nrf2 nuclear accumulation. Increased survival was
observed in PTP1B / mice injected with an APAP over-
dose (300 mg/kg) as compared with the wild-type control
(Figure 6a). Consistently, serum alanine transaminase (ALT)
was sevenfold higher in wild-type mice than in PTP1B /
mice at 6 and 24 h after injection (Figure 6b). Of note,
necrotic lesions were observed exclusively in livers of
wild-type mice (Figure 6c). Next, we analyzed the hepatic
expression of proinflammatory cytokines. At 6 h after
APAP injection, elevated IL6 and IL1b mRNA levels were
found in livers of wild-type mice, but not in PTP1B /
animals (Figure 6d). APAP decreased TNFa mRNA levels in
Figure 5 PTP1B modulates GSK3b/Src-Fyn-mediated Nrf2 nuclear accumulation in APAP-treated hepatocytes. (a) PTP1Bþ /þ immortalized hepatocytes were
transfected with control or GSK3b small interfering RNAs (siRNAs) (25 nM) for 48 h, followed by stimulation with 1 mM APAP. Nuclear and cytosolic extracts were analyzed by
western blot with antibodies against Nrf2, Fyn and Src. (b, upper panel) PTP1Bþ /þ immortalized hepatocytes were treated with PP2 (5 mM) for 30 min following 1 mM APAP
for different periods. Nrf2 in nuclear extracts was analyzed by western blot. (Lower panel) SYF / MEFs were treated with 1 mM APAP for different periods and Nrf2 was
analyzed in nuclear extracts by western blot. (c) PTP1Bþ /þ and PTP1B / immortalized hepatocytes were treated with 1 mM APAP for different periods. Phosphorylated
GSK3b (Tyr216) was analyzed in cytosolic extracts by western blot. Fyn and Src were analyzed in nuclear extracts. Similar results were obtained in three independent
experiments
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wild-type, but not in PTP1B-deficient mice. As hepatic
PTP1B expression is modulated by inflammation,29 we
performed the immunohistochemistry analysis. Increased
PTP1B staining was found in necrotic lesions of APAP-
treated wild-type mice after 6 h, particularly in areas
surrounding the central veins, but no signs of liver injury
were observed in sections from PTP1B / mice (Figure 6e).
We next determined if reduced sensitivity of PTP1B / mice
to APAP-induced liver injury was associated with alterations
in GSH levels. APAP administration depleted GSH at 3 and
6 h and increased APAP–protein adducts, these effects
being significantly ameliorated in the PTP1B / group
(Figure 6f). Protein carbonyl levels, an indicator of tissue
oxidative stress, were less elevated in APAP-injected
PTP1B / mice than in wild-type mice and paralleled the
reduced GSH depletion.
Figure 6 PTP1B-deficient mice are protected against APAP-induced, inflammation oxidative stress and liver damage. PTP1Bþ /þ and PTP1B / mice were injected
with 300 mg/kg APAP or saline for 6 or 24 h. (a) Survival curves after 24 h of APAP injection. (b) ALT activity at 6 and 24 h. (c) Representative images of whole livers from
PTP1Bþ /þ and PTP1B / mice 24 h after APAP injection. (d) IL6, IL1b and TNFa mRNA levels were determined by real-time polymerase chain reaction in livers from
PTP1Bþ /þ and PTP1B / mice at 6 h after APAP injection. (e) Representative anti-PTP1B immunostaining (left panel) and hematoxylin and eosin staining (right panel) in
livers from PTP1Bþ /þ and PTP1B / mice 6 h after APAP injection. Bar¼ 100mm. (f) GSH (left panel), APAP–protein adducts (middle panel) and carbonylated protein
levels (right panel) were analyzed in livers from PTP1Bþ /þ and PTP1B / mice at various time-periods after APAP injection. *Po0.05, **Po0.01 and ***Po0.005
PTP1B / versus PTP1Bþ /þ (n¼ 6–8 mice of each condition). Cys, cysteine. Veh, vehicle
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As intracellular redox state is chiefly regulated by Nrf2, we
examined differences in nuclear levels of Nrf2 in vivo. Nuclear
Nrf2 was detected in livers of wild-type mice at 3 and 6 h
after APAP treatment (Figure 7a). In PTP1B / animals,
basal nuclear Nrf2 was detected before APAP administration
and increased at 3 and 6 h after injection, where the
levels were higher than those of control mice. Similarly,
APAP-induced HO-1 protein content was higher in
PTP1B / mice. Then, we analyzed additional Nrf2 target
genes. mRNA levels of GPx, HO-1 and g-glutamyl cysteine
ligase modulatory subunit (GCL-M) significantly increased
at 3-h after APAP injection in livers of PTP1B / mice
as compared with the wild-type and GPx, g-glutamyl
cysteine ligase catalytic subunit (GCL-C), GCL-M and
NAD(P)H quinone oxidoreductase 1 (NQO1) mRNA increased
at 6 h (Figure 7b).
Figure 7 Beneficial effects of PTP1B deficiency on the induction of Nrf2-mediated antioxidant response and survival signaling in the liver. PTP1Bþ /þ and PTP1B /
mice were injected with 300 mg/kg APAP or saline for 3 or 6 h. (a) Western blot analysis of Nrf2 in nuclear extracts and HO-1, phospho (p)-JNK and JNK in total liver extracts.
(b) GPx, HO-1, GCL-M, GCL-C and NQO1 mRNA levels determined by quantitative real-time polymerase chain reaction (qRT-PCR) at 3 and 6 h after APAP injection.
*Po0.05, **Po0.01 and ***Po0.005 PTP1B / versus PTP1Bþ /þ (n¼ 6–8 mice of each condition). (c) Western blot analysis of phospho (p)-IGFIR, IGFIR, IRS1, IRS2,
phospho-Akt, Akt and BclxL levels in total liver extracts from PTP1Bþ /þ and PTP1B / mice 6 h after APAP injection. (d) Schematic diagram illustrating the proposed
mechanism by which PTP1B modulates Nrf2 nuclear accumulation. PTP1B might activate the unknown kinase upstream GSK3b by dephosphorylation, thereby triggering
activation of the GSK3b/Src-Fyn axis in the nucleus that ultimately leads to Nrf2 tyrosine phosphorylation, ubiquitination and degradation. Veh, vehicle
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Decreased JNK activation and sustained IGFIR/Akt/
BclxL survival signaling in APAP-treated PTP1B-defi-
cient mice. Activation of JNK was detected in APAP-treated
wild-type mice at 3 and 6 h after injection. As expected, this
effect decreased in PTP1B / mice (Figure 7a). Regarding
survival signaling, in wild-type mice IGFIR phosphorylation
was severely reduced at 6 h after APAP injection and IRS1
protein levels were downregulated in parallel with decreased
Akt phosphorylation (Figure 7c). Consistently, antiapoptotic
BclxL protein was barely detected at 6 h after APAP injection.
Conversely, APAP-treated PTP1B / mice maintained IGFIR
and Akt phosphorylation, as well as IRS1 and BclxL protein
content to similar levels than those of mice injected with saline.
Discussion
There is evidence of increased PTP1B expression during the
progression of non-alcoholic fatty liver disease that concurs
with insulin resistance and liver damage.30,31 However,
PTP1B functions in physiological responses regulated by
tyrosine kinase signaling, such as hepatocellular survival
during drug injury, are poorly understood. Our results
have unraveled a central role of PTP1B in the molecular
mechanism that mediates APAP-induced liver failure, identi-
fying PTP1B as a potential therapeutic target in the treatment
of human APAP hepatotoxicity. This study emerged from the
observation of elevated PTP1B expression in livers from
individuals suffering from APAP intoxication. Importantly, in
APAP-treated human and mouse hepatocytes, upregulation
of PTP1B preceded cell death.
Results in mouse hepatocytes demonstrated that PTP1B
deficiency attenuates cellular damage in response to APAP.
The fact that released LDH activity was reduced in PTP1B /
hepatocytes indicates that necrotic cell death was less severe
than in wild-type cells. In wild-type hepatocytes, APAP also
increased the percentage of sub-G0/G1 cells and release of
cytochrome C from the mitochondria. APAP also induced
activation of caspase-3 and decreased expression of anti-
apoptotic proteins BclxL and Mcl1. These results strongly
suggest that APAP also triggered apoptosis in hepatocytes
and, again, these effects were ameliorated by PTP1B
deficiency. The role of apoptosis in APAP-induced hepatocyte
cell death is controversial. However, there are studies that
clearly demonstrate both types of cell death following APAP
overdose. Circulating apoptotic and necrotic cell death markers
have been detected in patients with APAP-induced acute liver
injury.32–34 Cell death via necrosis and apoptosis has been
reported in the livers removed during transplantation because
of APAP intoxication.35 These data have also been shown in
mice during APAP poisoning.36 In light of these results, we and
others have shown that PTP1B inhibition protects hepatocytes
against activation of mitochondrial (intrinsic) and death
receptor (extrinsic)-mediated apoptotic pathways,21,25 reinfor-
cing the role of this phosphatase in programmed cell death.
As cellular oxidative stress processes (GSH depletion and
ROS generation)13 are ameliorated in PTP1B / hepato-
cytes, we investigated the modulation of oxidative stress by
PTP1B. An unknown tyrosine kinase has been proposed to be
the upstream activator of GSK3b by phosphorylation at
Tyr216.27,28 This phenomenon leads to SKF-mediated
tyrosine phosphorylation, nuclear export, ubiquitination and
degradation of Nrf2 in response to oxidative stress inducers.
Our data demonstrated firstly that this signaling pathway is
activated by APAP in hepatocytes and secondly that PTP1B
deficiency mimics the inhibition of GSK3b or SKF on the
downstream mediators of this pathway. Inhibition of GSK3b or
SKF augmented and prolonged Nrf2 nuclear accumulation,
delaying its nuclear exclusion in response to APAP.
Importantly, the effect of PTP1B deficiency on this pathway
was manifested by delayed Src-Fyn nuclear translocation,
Nrf2 tyrosine phosphorylation and its subsequent ubiquitina-
tion and degradation, leading to enhanced HO-1 induction.
These results suggest that PTP1B might activate this
unknown kinase upstream from GSK3b, probably by
dephosphorylation, and thereby triggering the activation of
the GSK3b/Src-Fyn axis that ultimately leads to Nrf2
degradation. Consequently, as demonstrated in hepatocytes,
PTP1B deficiency might delay and/or reduce activation of this
complex axis, resulting in prolonged nuclear accumulation of
Nrf2 and enhanced antioxidant defense.
Besides the novel role of PTP1B in antioxidant defense
reported herein, this phosphatase regulates duration and/or
intensity of survival signals emerging from the tyrosine kinase
receptor family.19–21 As IGFIR triggers survival responses in
hepatocytes,37 the lack of PTP1B prevented the reduction in
IGFIR/IRS1/2/Akt-mediated survival signaling in APAP-
treated cells. In fact, this is the first report showing degrada-
tion of IRS proteins in hepatocytes by APAP, suggesting that
high doses of this analgesic may also interfere with hepatic
insulin signaling and increase the risk of metabolic diseases
such as type 2 diabetes mellitus. Thus, in wild-type hepatocytes,
increased ROS-mediated JNK and p38 MAPK phosphorylation
by APAP are likely to be responsible for the feedback
mechanism on IGFIR-mediated signaling, leading to IRS1/2
serine phosphorylation that precedes degradation.38 In the
absence of PTP1B, the decrease in ROS-mediated activation of
JNK and p38 MAPK and the increase in IGFIR tyrosine
phosphorylation might act in conjunction with the effects on
the GSK3b/Src-Fyn axis, resulting in attenuated oxidative stress
and increased cell survival in response to APAP.
Several studies have shown the mechanistic importance of
hepatic cytokines in APAP-induced liver injury. In the liver,
cytokines are mainly produced by non-parenchymal cells. Our
in vivo data show significant lower expression levels of IL1b
and IL6 mRNAs in the livers of PTP1B / mice upon APAP
injection as compared with the elevated levels of the wild-type
controls, suggesting that PTP1B also modulates cytokine
production by non-parenchymal (i.e. Kupffer) cells in
response to liver damage. Cytokines have an essential role
as inducers of PTP1B in metabolic diseases. Activation of
JNK together with elevated expression of PTP1B in response
to IL6 has been reported in skeletal muscle of insulin-resistant
mice.39 Likewise, IL4 induces PTP1B to suppress IL4-induced
STAT6 signaling in B cells.40 As PTP1B is increased in the
livers of APAP-injected wild-type mice, this effect is likely to be
due to elevation of IL6 and IL1b. Therefore, cytokine-
mediated increases in PTP1B expression might enhance
the GSK3b/Src-Fyn axis, resulting in increased Nrf2 tyrosine
phosphorylation and a rapid nuclear exclusion. Moreover, in
the liver of APAP-injected wild-type mice, the negative
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cross-talk elicited by JNK on IRS proteins and also by PTP1B
by direct dephosphorylation of the IGFIR might synergize with
the enhancement of the GSK3b/Src-Fyn axis to reduce
survival of hepatocytes in vivo. This mechanism is supported
by lower activation of JNK, higher IGFIR tyrosine phosphory-
lation and nuclear Nrf2 accumulation in livers of APAP-
injected PTP1B / mice as compared with the wild-type
controls. As a result, PTP1B-deficient livers are protected
against APAP-induced oxidative stress and injury as mani-
fested by decreased GSH depletion favoring NAPQI
detoxification and subsequently limiting the formation of
APAP–protein adducts. However, the effects of APAP
in vivo are not exclusively mediated by elevation of PTP1B
expression induced by proinflammatory cytokines secreted by
non-parenchymal cells; our in vitro data have also demon-
strated direct effects of APAP in hepatocytes. Nevertheless,
PTP1B deficiency protects against damage in hepatocytes in
culture and in whole liver, reinforcing the regulatory role of this
phosphatase in multiple molecular mechanisms triggered in
response to APAP in distinct liver cells.
As summarized in Figure 7d, we have demonstrated the
unique role of PTP1B in the liver as a critical crossroad in the
signaling pathways triggered in response to APAP by dual
modulation of the Nrf2-mediated antioxidant response
through the GSK3b/Src-Fyn kinases axis and the survival
signaling through its effects on the IGFIR/IRSs/Akt signaling
pathway. Collectively, our data suggest that inhibition of
PTP1B would be a suitable therapeutic approach against
APAP-induced hepatotoxicity.
Materials and Methods
Reagents and antibodies. Fetal bovine serum and culture media were
obtained from Invitrogen (Carlsbad, CA, USA). Protein A agarose was purchased
from Roche Diagnostics. APAP and MG132 were from Sigma-Aldrich (St. Louis,
MO, USA). PP2 was purchased from Tocris Bioscience (Ellsville, MO, USA). The
antibodies used in this study were: anti-cleaved (Asp175) caspase-3 (no. 9661),
anti-phospho-JNK (Thr183/Tyr185) (no. 4668), anti-phospho-p38 MAPK (Thr180/
Tyr182) (no. 9211), anti-p38 MAPK (no. 9212), anti-Akt (no. 9272), and anti-
ubiquitin (no. 3936) antibodies were from Cell Signaling Technology (Danvers,
MA, USA). Anti-Bclx (no. 610211), anti-phospho-GSK3b (no. 612312), anti-
GSK3b (no. 6102019) and anti-cytochrome C (no. 556433) antibodies were from
BD Biosciences (San Diego, CA, USA). Anti-phospho-IGF-IR (Tyr1165/1166)
(sc-101704), anti-JNK (sc-571), anti-phospho-Akt1/2/3 (Ser473) (sc-7985-R), anti-
Nrf2 (C-20, sc-722), anti-Mcl1 (sc-819), anti-Fyn (sc-16), anti-Keap1 (sc-33569),
anti-Lamin B (sc-20682 in Figure 4b) and anti-human PTP1B (sc-14021) were
from Santa Cruz Biotechnology (Palo Alto, CA, USA). The anti-IRS1 (06-248),
anti-IRS2 (06-506), anti-p85a (06-195), anti-mouse PTP1B (07-088), anti-HO1
(AB1284), anti-phospho-Ser (clone 4A4, 05-1000X) and anti-phospho-Tyr (clone
4G10, 05-321) antibodies were purchased from Merck Millipore (Merck KGaA,
Darmstadt, Germany). Anti-IGF-IR antibody was a gift from S Pons (CSIC, Madrid,
Spain). Anti-b-actin (A-5441) antibody was from Sigma Chemical Co. (St. Louis,
MO, USA). Anti-Lamin B (aB16048) and anti-Cyp2e1 antibody (aB19140) were from
Abcam (Cambridge, UK). Mouse monoclonal antibody (mAb) 327 against c-Src was
from Calbiochem (Merck KGaA, Darmstadt, Germany). Anti-cytochrome C oxidase
subunit I antibody (A-6403) was from Molecular Probes (Eugene, OR, USA).
Human liver biopsies. Human liver samples were obtained from the
Department of Pathology, University of Edinburgh (Edinburgh, UK). Written
informed consent was obtained from each patient. Characteristics of five patients
transplanted following APAP overdose are shown in Table 1.
Animal models. Three-month-old male PTP1Bþ /þ (wild-type) and
PTP1B / mice on the C57Bl/6J 129Sv/J genetic background and maintained
as described previously41 were used throughout this study. Animal experimenta-
tion was approved by the ethic committee at CSIC and was conducted according
to the accepted guidelines for animal care of the Comunidad de Madrid (Spain).
Overnight fasted mice were intraperitoneally (i.p.) injected with 300 mg/kg APAP
dissolved in physiological saline. Mice were killed at 1, 3, 6 and 24 h and livers and
blood were collected.
Cell culture. Human hepatocytes were prepared from liver biopsies obtained
from 12 patients (eight male, four female aged 58±4.0 years) submitted to a
surgical resection for liver tumors after obtaining patients’ written consent.
Hepatocytes’ isolation was based on the two-step collagenase procedure.42
Mouse hepatocytes were isolated from male mice (8–12 weeks old) by perfusion
with collagenase and cultured as described.41 CHLs, purchased from the ATCC,
(Manassas, VA, USA) were a gift from P Martin-Sanz (CSIC). The generation and
characterization of immortalized hepatocyte cell lines from wild-type and PTP1B /
 mice has been described previously.43 Cells were grown in DMEM plus 10%
heat-inactivated fetal calf serum and stimulated with various doses of APAP.
Liver histology. Histological grading of hepatic necrosis was performed by
two blinded observers using hematoxylin and eosin (H&E)-stained sections as
follows: 30% of the total area necrotic (one point); 30–60% of the total area
necrotic (two points); and 60% of the total area necrotic (three points). PTP1B
immunohistochemistry was performed as described previously.44
Analysis of ALT activity. Blood was collected in tubes containing heparin
and diluted 1/30 with saline (0.9% NaCl). ALT activity was determined by direct
measurement with the Reflotron test (Ref. 10745120; Roche Diagnostics,
Indianapolis, IN, USA).
Transient transfection with siRNA. siRNA oligonucleotides were
synthesized by Dharmacon RNAi Technologies (Fisher Scientific-USA, Pittsburgh,
PA, USA) for gene silencing of mouse PTP1B and GSK3b. Wild-type immortalized
hepatocytes were seeded in 6-cm dishes and incubated overnight at 37 1C with
5% CO2. When 40–50% confluence was reached, cells were transfected with
10 nM of PTP1B or 25 nM GSK3b siRNAs or with a scrambled control siRNA
following DharmaFECT General Transfection Protocol. After 48 h, cells were used
for experiments.
Immunofluorescence. Cells were grown in glass coverslips until 80%
confluence was reached. Then, cells were washed two times with PBS, fixed in
methanol ( 20 1C) for 2 min and processed to immunofluorescence. Primary
anti-Nrf2 antibody was applied for 1 h at 37 1C in PBS–1% bovine serum albumin
(BSA), followed by 4 5 min washes in PBS, a 45-min incubation with
fluorescence-conjugated secondary antibody (Alexa 488 goat anti-rabbit) and
Table 1 Demographic and biochemical characteristics of patients with APAP hepatotoxicity
Patient
number
Age
(years)
Sex Acetaminophen
dose
Staggered
overdose
Admission alanine
aminotransferase (IU/l)
Admission
creatinine (lmol/l)
Prothrombin
time (s)
Overdose to
transplant (h)
1 42 Female 32 g No 12755 218 77 212
2 43 Female NA NA 7106 192 182 NA
3 48 Male 16 g Yes 20800 124 96 NA
4 45 Female 10 g No 1097 142 69 176
5 36 Male 50 g No 9847 152 87 70
NA, not available
Normal range alanine aminotransferase 10–50 IU/l, creatinine 60—120 mmol/l and prothrombin time 10.2–12.7 s
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four final washes of 5 min each in PBS. Immunofluorescence was examined in a
Nikon Eclipse 90i microscope (Nikon Instruments, Inc., Melville, NY, USA).
Immunofluorescence mounting medium was from Vector Laboratories Inc.
(Burlingame, CA, USA). For 4,6-diamidino-2-phenylindole (DAPI) staining, cells
were washed with PBS, fixed in methanol ( 20 1C) for 2 min and stained with
1mM DAPI for 5 min in the dark. After washing with PBS, nuclear morphology was
analyzed by fluorescence microscopy.
Evaluation of cell viability by LDH leakage assay. Cellular damage
was evaluated by LDH leakage assay as described.45
Analysis of cellular viability by crystal violet. After cell incubation
with APAP, the medium was discarded, and the remaining viable adherent cells
were stained with crystal violet (0.2% (w/v) in 2% ethanol) for 20 min. After this
time, plates were rinsed with tap water and allowed to dry, and 1% SDS was
added to solubilize them. The absorbance of each plate was read spectro-
photometrically at 560 nm. Dishes without cells were processed in parallel to
correct the nonspecific adhesion of crystal violet to the plastic. The remaining
viable cells were calculated as the percentage of absorbance with respect to
control cells (incubated in the absence of APAP).
Quantification of apoptotic cells by flow cytometry. After induction
of apoptosis, adherent and non-adherent cells were collected by centrifugation,
washed with PBS and fixed with cold ethanol. The cells were then washed,
resuspended in PBS and incubated with RNAse A (25mg/106 cells) for 30 min at
37 1C. After addition of 0.05% propidium iodide, cells were analyzed by flow cytometry.
Analysis of caspase-3 activity. Cells were scraped off, collected by
centrifugation at 2500 g for 5 min and lysed at 4 1C in 5 mM Tris/HCl (pH 8),
20 mM EDTA and 0.5% Triton X-100. Caspase-3 activity was determined as
described previously.25 Protein concentration of cell lysates was determined, and
the results are presented as caspase-3 activity per micrograms of total protein.
Luciferase assays. HEK 293T cells were seeded on 24-well plates (100 000
cells per well), cultured for 16 h and transfected using calcium phosphate.
Transient transfections of HEK 293T cells were performed with the expression
vectors for pcDNA3.1mNrf2-V5/HisB (a gift from Dr. JD Hayes, Biomedical
Research Institute, Ninewells Hospital and Medical School, University of Dundee,
Dundee, UK), Renilla (Promega, Madison, WI, USA) and 3ARE-Luc (a gift from
Dr. J Alam, Department of Molecular Genetics, Ochsner Clinic Foundation, Baton
Rouge, LA, USA) combined with myc-PTP1B (a gift from Dr. M Tremblay,
Department of Biochemistry, McGill University, Montreal, QC, Canada) only in the
indicated cases. After transfection, cells were treated with vehicle (PBS), APAP
(10 and 20 mM) or tert-butyl hydroquinone (tBHQ) (15 mM) for 16 h. Cells were
lysed and assayed for luciferase activity with the dual luciferase assay system
(Promega), according to the manufacturer’s instructions. Relative light units were
measured in a GloMax 96 microplate luminometer with dual injectors (Promega,
Madison, WI, USA).
Homogenization and preparation of tissue extracts. Frozen livers
were homogenized in 16 volumes (w/v) of ice-cold lysis buffer containing 50 mM
Tris-HCl, 1% Triton X-100, 2 mM EGTA, 10 mM EDTA acid, 100 mM NaF, 1 mM
Na4P2O7, 2 mM Na3VO4, 100mg/ml phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml
aprotinin, 1mg/ml pepstatin A and 1mg/ml leupeptin. Livers were homogenized in
the same lysis buffer using the Brinkman PT 10/35 Polytron (American Laboratory
Trading, Inc. East Lyme, CT, USA). Extracts were kept ice-cold at all times. Liver
extracts were cleared by microcentrifugation at 40 000 g for 20 min at 4 1C. The
supernatant was aliquoted and stored at  70 1C.
Protein determination. Protein determination was performed by the
Bradford dye method, using the Bio-Rad reagent and BSA as the standard.
Immunoprecipitations and western blot. To obtain total cell lysates,
cells from supernatants were collected by centrifugation at 2000 g for 5 min at
4 1C. Attached cells were scraped off in ice-cold PBS, pelleted by centrifugation at
4000 g for 10 min at 4 1C and resuspended in lysis buffer (25 mM HEPES,
2.5 nM EDTA, 0.1% Triton X-100, 1 mM PMSF and 5 mg/ml leupeptin). Cellular
lysates were clarified by centrifugation at 12 000 g for 10 min. After protein
content determination, equal amounts of protein (600mg–1 mg) were
immunoprecipitated at 4 1C with the corresponding antibodies. The immune
complexes were collected on agarose beads and submitted to western blot
analysis. After SDS-PAGE, gels were transferred to Immobilon membranes and
were blocked using 5% non-fat dried milk or 3% BSA in 10 mM Tris-HCl, 150 mM
NaCl (pH 7.5) and incubated overnight with antibodies as indicated in 0.05%
Tween-20, 10 mM Tris-HCl and 150 mM NaCl (pH 7.5). Immunoreactive bands
were visualized using the ECL Western blotting protocol (Millipore).
Extraction of nuclear and cytosolic proteins. Cells and liver were
resuspended at 4 1C in 10 mM HEPES-KOH (pH 7.9), 1.5 mM MgCl2, 10 mM KCl,
0.5 mM DTT, 0.2 mM PMSF, 0.75mg/ml leupeptin, 0.75mg/ml aprotinin (Buffer A),
allowed to swell on ice for 10 min, and then vortexed for 10 s. Samples were
centrifuged and the supernatant containing the cytosolic fraction was stored at
 70 1C. The pellet was resuspended in cold buffer C (20 mM HEPES-KOH
(pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT,
0.2 mM PMSF, 0.75mg/ml leupeptin, 0.75mg/ml aprotinin) and incubated on ice
for 20 min for high salt extraction. Cellular debris was removed by centrifugation
for 2 min at 4 1C, and the supernatant fraction was stored at  70 1C.
Isolation of mitochondrial and cytosolic extracts. At the end of the
culture time, cells were recovered by scrapping and collected by centrifugation at
2500 g for 5 min at 4 1C. Mitochondrial and cytosolic extracts were obtained as
described previously.25
Determination of GSH. The content of GSH was quantified by the
fluorometric assay of Hissin and Hilf.46
Determination of GPx and GR enzymatic activities. Cells were
collected in PBS and centrifuged at low speed (300 g) for 5 min to pellet cells.
Cell pellets were resuspended in 20 mM Tris containing 5 mM EDTA and 0.5 mM
mercaptoethanol, submitted to ultrasound and centrifuged at 3000 g for 15 min.
Enzyme activities were measured in the supernatants as described.47
Measurement of intracellular ROS. For visualization and analysis of
intracellular ROS by flow cytometry, the oxidation-sensitive DCFH-DA probe was
used. Cells were detached by trypsinization and the cellular fluorescence intensity
was measured after 30-min incubation with 5mM DCFH-DA by using a FACScan
flow cytometer (BD Biosciences, San Jose´, CA, USA). For each analysis, 10 000
events were recorded.
Determination of protein carbonyl content. Protein oxidation of liver
homogenates was measured as carbonyl groups’ content according to the method
of Richert et al.48
Determination of APA–protein adducts. Analysis of APAP covalently
bound to proteins in liver was measured by initial protease treatment of liver
homogenates, followed by high-performance liquid chromatography-electrochemical
analysis for APAP-cysteine as described previously.49
Quantitative real-time PCR analysis and primer sequence. Total
RNA was extracted with Trizol (Invitrogen) and reverse transcribed using a
SuperScriptTM III First-Strand Synthesis System for qPCR following the manufac-
turer’s indications (Invitrogen). qPCR was performed with an ABI 7900 sequence
detector (Invitrogen) using the SyBr Green method and d(N)6 random hexamer with
the primers indicated in Supplementary Table 1. Primer-probe sets for mouse PTP1B,
TNFa, IL6 and IL1b were purchased as predesigned TaqMan gene expression
assays (Applied Biosystems, Life Technologies, Carlsbad, CA, USA).
Data analysis. Data are expressed as mean±S.E.M. Comparisons between
groups were made using one-way ANOVA. For qRT-PCR, a two-way ANOVA test
followed by a Bonferroni’s post-test was used. Differences were considered to be
statistically significant at Po0.05. The data were analyzed with the SPSS
(windows statistical package, version 9.0.1, SPSS Inc., Chicago, IL, USA).
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